Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans

These results provide evidence that the glutamatergic NMDA receptor may contribute to psychotic symptom formation via modulation of the DA system

Franz X Vollenweider

2002

Scholarcy highlights

  • Administration of the N-methyl-d-aspartate antagonist S-ketamine in normals produces a psychosis-like syndrome including several positive and negative symptoms of schizophrenic disorders (Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH
  • Given the clinical efficacy of dopamine D2 receptor antagonists in the treatment of positive symptoms, it is conceivable that S-ketamine-induced psychotic symptoms are partially due to a secondary activation of dopaminergic systems
  • The change in raclopride binding potential in the ventral striatum correlated with heightened mood ranging from euphoria to grandiosity
  • These results provide evidence that the glutamatergic NMDA receptor may contribute to psychotic symptom formation via modulation of the DA system

Need more features? Save interactive summary cards to your Scholarcy Library.